MapLight Therapeutics
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia (NCT07459647) | MapLight Therapeutics | 2026-03-31 |
| An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis (NCT07459660) | MapLight Therapeutics | 2026-03-25 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis (NCT06887192) | MapLight Therapeutics | 2025-08-15 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia (NCT07038876) | MapLight Therapeutics | 2025-06-27 |
| ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) (NCT05889273) | MapLight Therapeutics | 2023-06-01 |
| ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) (NCT05081245) | MapLight Therapeutics | 2022-09-13 |
Track MapLight Therapeutics automatically
Every clearance here is in the API, with alerts when new ones post.